Phase I dose-escalation trial of mepacrine in patients with liver metastases or advanced liver cancer.
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2014
At a glance
- Drugs Mepacrine (Primary)
- Indications Liver cancer; Liver metastases
- Focus Adverse reactions
- Sponsors Cleveland BioLabs
- 16 Apr 2014 Results published in a Cleveland BioLabs media release.
- 16 Apr 2014 Primary endpoint 'Maximum-tolerated-dose' has been met.
- 16 Apr 2014 Status changed from recruiting to completed, according to a Cleveland BioLabs media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History